Correction to Lancet Oncol 2017; 18: 1274–84 (The Lancet Oncology (2017) 18(9) (1274–1284) (S1470204517304692) (10.1016/S1470-2045(17)30469-2));Olaparib tablets as maintenance therapy in patients with platinum-sensitive, relapsed ovarian cancer and a BRCA1/2 mutation (SOLO2/ENGOT-Ov21): a double-blind, randomised, placebo-controlled, phase 3 trial

The Lancet Oncology

Volumn 18, Issue 9, 2017, Pages 1274-1284

  Pujade Lauraine, Eric ^a   Ledermann, Jonathan A ^b   Selle, Frédéric ^c,t   Gebski, Val ^d   Penson, Richard T ^e   Oza, Amit M ^f,t   Korach, Jacob ^g,t   Huzarski, Tomasz ^h,t   Poveda, Andrés ⁱ   Pignata, Sandro ^j,t   Friedlander, Michael ^k,t   Colombo, Nicoletta ^l,t   Harter, Philipp ^m,t   Fujiwara, Keiichi ⁿ   Ray Coquard, Isabelle Laure ^o,t   Banerjee, Susana ^p,t   Liu, Joyce ^q   Lowe, Elizabeth S ^r   Bloomfield, Ralph ^r   Pautier, Patricia ^s,t   Byrski, Tomasz ^t   Scambia, Giovanni ^t   Nicoletto, Maria ^t   Nussey, Fiona ^t   Clamp, Andrew ^t   Penson, Richard ^t   Poveda Velasco, Andrés ^t   Rodrigues, Manuel ^t   Lotz, Jean Pierre ^t   Provencher, Diane ^t   Prat Aparicio, Aleix ^t   Vidal Boixader, Laura ^t   Scott, Clare ^t   Tamura, Kenji ^t   Yunokawa, Mayu ^t   Lisyanskaya, Alla ^t   Medioni, Jacques ^t   Pécuchet, Nicolas ^t   Dubot, Coraline ^t   de la Motte Rouge, Thibault ^t   Kaminsky, Marie Christine ^t   Weber, Béatrice ^t   Lortholary, Alain ^t   Parkinson, Christine ^t   Ledermann, Jonathan ^t   Williams, Sarah ^t   Cosin, Jonathan ^t   Hoffman, James ^t   Plante, Marie ^t   Covens, Allan ^t   Sonke, Gabe ^t   Joly, Florence ^t   Floquet, Anne ^t   Hirte, Holger ^t   Amit, Amnon ^t   Park Simon, Tjoung Won ^t   Matsumoto, Koji ^t   Tjulandin, Sergei ^t   Kim, Jae Hoon ^t   Gladieff, Laurence ^t   Sabbatini, Roberto ^t   O'Malley, David ^t   Timmins, Patrick ^t   Kredentser, Daniel ^t   Laínez Milagro, Nuria ^t   Barretina Ginesta, Maria Pilar ^t   Tibau Martorell, Ariadna ^t   Gómez de Liaño Lista, Alfonso ^t   Ojeda González, Belén ^t   Mileshkin, Linda ^t   Mandai, Masaki ^t   Boere, Ingrid ^t   Ottevanger, Petronella ^t   Nam, Joo Hyun ^t   Filho, Elias ^t   Hamizi, Salima ^t   Cognetti, Francesco ^t   Warshal, David ^t   Dickson Michelson, Elizabeth ^t   Kamelle, Scott ^t   McKenzie, Nathalie ^t   Rodriguez, Gustavo ^t   Armstrong, Deborah ^t   Chalas, Eva ^t   Celano, Paul ^t   Behbakht, Kian ^t   Davidson, Susan ^t   Welch, Stephen ^t   Helpman, Limor ^t   Fishman, Ami ^t   Bruchim, Ilan ^t   Sikorska, Magdalena ^t   Słowińska, Anna ^t   Rogowski, Wojciech ^t   Bidziński, Mariusz ^t   Śpiewankiewicz, Beata ^t   Casado Herraez, Antonio ^t   Mendiola Fernández, César ^t   Gropp Meier, Martina ^t   Saito, Toshiaki ^t   Takehara, Kazuhiro ^t   Enomoto, Takayuki ^t   Watari, Hidemichi ^t   Choi, Chel Hun ^t   Kim, Byoung Gie ^t   Kim, Jae Weon ^t   Hegg, Roberto ^t   Vergote, Ignace ^t   more..

^a UNIVERSITÉ PARIS DESCARTES   (France)

^b UNIVERSITY COLLEGE LONDON   (United Kingdom)

^c HÔPITAL TENON   (France)

^d UNIVERSITY OF SYDNEY   (Australia)

^e MASSACHUSETTS GENERAL HOSPITAL   (United States)

^f PRINCESS MARGARET HOSPITAL   (Canada)

^g TEL AVIV UNIVERSITY   (Israel)

^h POMERANIAN MEDICAL UNIVERSITY   (Poland)

ⁱ INSTITUTO VALENCIANO DE ONCOLOGÍA   (Spain)

^j NATIONAL CANCER INSTITUTE   (Italy)

^k UNIVERSITY OF NEW SOUTH WALES   (Australia)

^l UNIVERSITY OF MILANO BICOCCA   (Italy)

^m KLINIKEN ESSEN MITTE   (Germany)

ⁿ SAITAMA MEDICAL UNIVERSITY INTERNATIONAL MEDICAL CENTER   (Japan)

^o CENTRE LÉON BÉRARD   (France)

^p INSTITUTE OF CANCER RESEARCH   (United Kingdom)

^q DANA FARBER CANCER INSTITUTE   (United States)

^r ASTRAZENECA   (United Kingdom)

^s INSTITUT GUSTAVE ROUSSY   (France)

^t NONE

more..

Author keywords

[No Author keywords available]

Indexed keywords

BRCA1 PROTEIN; BRCA2 PROTEIN; OLAPARIB; PLACEBO; ANTINEOPLASTIC AGENT; PHTHALAZINE DERIVATIVE; PIPERAZINE DERIVATIVE; TABLET;

ABDOMINAL PAIN; ACUTE MYELOID LEUKEMIA; ADULT; ANEMIA; ARTICLE; ASTHENIA; CANCER CHEMOTHERAPY; CANCER GRADING; CANCER RECURRENCE; CANCER SURVIVAL; CLINICAL EFFECTIVENESS; CONSTIPATION; CONTROLLED STUDY; DISEASE SEVERITY; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; DRUG SAFETY; ENDOMETRIOID CARCINOMA; FATIGUE; FEMALE; HUMAN; HUMAN TISSUE; INTESTINE OBSTRUCTION; MAINTENANCE THERAPY; MAJOR CLINICAL STUDY; MIDDLE AGED; MULTICENTER STUDY; MUTATION; NEUTROPENIA; OVARY CANCER; PHASE 3 CLINICAL TRIAL; PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; RANDOMIZED CONTROLLED TRIAL; TABLET FORMULATION; TREATMENT OUTCOME; TREATMENT PLANNING; UTERINE TUBE CARCINOMA; CLINICAL TRIAL; GENETICS; MAINTENANCE CHEMOTHERAPY; OVARIAN NEOPLASMS; PATHOLOGY; TABLET; TUMOR SUPPRESSOR GENE;

ANTINEOPLASTIC AGENTS; DOUBLE-BLIND METHOD; FEMALE; GENES, BRCA1; GENES, BRCA2; HUMANS; MAINTENANCE CHEMOTHERAPY; MIDDLE AGED; MUTATION; OVARIAN NEOPLASMS; PHTHALAZINES; PIPERAZINES; TABLETS;

EID: 85025811245     PISSN: 14702045     EISSN: 14745488     Source Type: Journal    
DOI: 10.1016/S1470-2045(17)30639-3     Document Type: Erratum

References (21)

1. Hanker, LC, Loibl, S, Burchardi, N, et al. The impact of second to sixth line therapy on survival of relapsed ovarian cancer after primary taxane/platinum-based therapy. Ann Oncol 23 (2012), 2605–2612.
2. Ledermann, J, Harter, P, Gourley, C, et al. Olaparib maintenance therapy in patients with platinum-sensitive relapsed serous ovarian cancer: a preplanned retrospective analysis of outcomes by BRCA status in a randomised phase 2 trial. Lancet Oncol 15 (2014), 852–861.
3. Ledermann, JA, Rustin, GJ, Hackshaw, A, et al. Randomized phase II placebo-controlled trial of maintenance therapy using the oral triple angiokinase inhibitor BIBF 1120 after chemotherapy for relapsed ovarian cancer. J Clin Oncol 29 (2011), 3798–3804.
4. Bryant, HE, Schultz, N, Thomas, HD, et al. Specific killing of BRCA2-deficient tumours with inhibitors of poly(ADP-ribose) polymerase. Nature 434 (2005), 913–917.
5. Farmer, H, McCabe, N, Lord, CJ, et al. Targeting the DNA repair defect in BRCA mutant cells as a therapeutic strategy. Nature 434 (2005), 917–921.
6. Alsop, K, Fereday, S, Meldrum, C, et al. BRCA mutation frequency and patterns of treatment response in BRCA mutation-positive women with ovarian cancer: a report from the Australian Ovarian Cancer Study Group. J Clin Oncol 30 (2012), 2654–2663.
7. Cancer Genome Atlas Research Network. Integrated genomic analyses of ovarian carcinoma. Nature 474 (2011), 609–615.
8. Zhang, S, Royer, R, Li, S, et al. Frequencies of BRCA1 and BRCA2 mutations among 1,342 unselected patients with invasive ovarian cancer. Gynecol Oncol 121 (2011), 353–357.
9. Dann, RB, DeLoia, JA, Timms, KM, et al. BRCA1/2 mutations and expression: response to platinum chemotherapy in patients with advanced stage epithelial ovarian cancer. Gynecol Oncol 125 (2012), 677–682.
10. European Medicines Agency. Lynparza summary of product characteristics. http://www.ema.europa.eu/docs/en_GB/document_library/EPAR_-_Product_Information/human/003726/WC500180151.pdf, 2014 (accessed May 30, 2017).
11. FDA. Lynparza: highlights of prescribing information. http://www.accessdata.fda.gov/drugsatfda_docs/label/2014/206162lbl.pdf, 2014 (accessed May 30, 2017).
12. Ledermann, J, Harter, P, Gourley, C, et al. Olaparib maintenance therapy in platinum-sensitive relapsed ovarian cancer. N Engl J Med 366 (2012), 1382–1392.
13. Ledermann, JA, Harter, P, Gourley, C, et al. Overall survival in patients with platinum-sensitive recurrent serous ovarian cancer receiving olaparib maintenance monotherapy: an updated analysis from a randomised, placebo-controlled, double-blind, phase 2 trial. Lancet Oncol 17 (2016), 1579–1589.
14. Mateo, J, Moreno, V, Gupta, A, et al. An adaptive study to determine the optimal dose of the tablet formulation of the PARP inhibitor olaparib. Target Oncol 11 (2016), 401–415.
15. European Medicines Agency. ICH topic E6(R1): Guideline for good clinical practice. International Conference on Harmonisation of Technical Requirements for Registration of Pharmaceuticals for Human Use. https://www.ich.org/fileadmin/Public_Web_Site/ICH_Products/Guidelines/Efficacy/E6/E6_R1_Guideline.pdf, 1996 (accessed May 30, 2017).
16. US Food and Drug Administration. Drug Approval Package: Zejula (niraparib). Multi-discipline review/summary, clinical, non-clinical. https://www.accessdata.fda.gov/drugsatfda_docs/nda/2017/208447_zejula_toc.cfm, 2017 (accessed May 30, 2017).
17. Mirza, MR, Monk, BJ, Herrstedt, J, et al. Niraparib maintenance therapy in platinum-sensitive, recurrent ovarian cancer. N Engl J Med 375 (2016), 2154–2164.
18. Swisher, EM, Lin, KK, Oza, AM, et al. Rucaparib in relapsed, platinum-sensitive high-grade ovarian carcinoma (ARIEL2 Part 1): an international, multicentre, open-label, phase 2 trial. Lancet Oncol 18 (2017), 75–87.
19. Matulonis, UA, Oza, AM, Ho, TW, Ledermann, JA, Intermediate clinical endpoints: a bridge between progression-free survival and overall survival in ovarian cancer trials. Cancer 121 (2015), 1737–1746.
20. Wilson, MK, Pujade-Lauraine, E, Aoki, D, et al. Fifth Ovarian Cancer Consensus Conference of the Gynecologic Cancer InterGroup: recurrent disease. Ann Oncol 28 (2017), 727–732.
21. Dougherty, BA, Lai, Z, Hodgson, DR, et al. Biological and clinical evidence for somatic mutations in BRCA1 and BRCA2 as predictive markers for olaparib response in high-grade serous ovarian cancers in the maintenance setting. Oncotarget 8 (2017), 43653–43661.